{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:45:30Z","timestamp":1792118730846,"version":"4.4.0"},"reference-count":73,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"DOI":"10.1080\/14656566.2026.2750237","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:49:37Z","timestamp":1791971377000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Targeted pharmacotherapy of NF1-associated plexiform neurofibromas: current evidence and future perspectives"],"prefix":"10.1080","author":[{"given":"Laura","family":"Fertitta","sequence":"first","affiliation":[{"name":"Referral Center for Neurofibromatoses, Henri Mondor Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris Est Cr\u00e9teil University","place":["Cr\u00e9teil, France"]},{"name":"INSERM U955, Mondor Institute of Biomedical Research","place":["Cr\u00e9teil, France"]},{"name":"Henri Mondor Hospital, Assistance Publique-H\u00f4pitaux Paris","place":["Cr\u00e9teil, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-8762","authenticated-orcid":false,"given":"Eric","family":"Pasmant","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, CARPEM","place":["Paris, France"]},{"name":"Institut Curie","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.33139"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01170-5"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.4"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3911"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/AHMT.S303456"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy067"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.39.5.311"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.3576"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011811-132441"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-8467(97)81805-7"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/90148"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.12.027"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184513"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.08.041"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60578"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25546"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605943"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912735"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf101"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae121"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03361-4"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00986-9"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0069"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01034"},{"key":"e_1_3_4_27_1","unstructured":"Gomekli (mirdametinib): US prescribing information. Stamford CT: SpringWorks Therapeutics; 2025 [cited 2026 Sep 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219379s000lbl.pdf"},{"key":"e_1_3_4_28_1","unstructured":"Ezmekly (mirdametinib): EPAR - product information. Amsterdam: European Medicines Agency; 2025 [cited 2026 Oct 9]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ezmekly"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2558656"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01176-y"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02927-2"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.10044"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.3017"},{"key":"e_1_3_4_34_1","unstructured":"US Food and Drug Administration. NDA multi-disciplinary review and evaluation: koselugo (selumetinib) NDA 213756. Silver Spring MD: FDA; 2020 [cited 2026 Oct 10]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213756Orig1s000MultidisciplineR.pdf"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae223"},{"key":"e_1_3_4_36_1","unstructured":"Tunlametinib in adults with NF1 and inoperable plexiform neurofibroma. ClinicalTrials.Gov identifier: NCT05331105. Bethesda MD: National Library of Medicine; [cited 2026 Sep 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05331105"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noag112"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa222.619"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells15050434"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0905833106"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001431"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1365"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202503359"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7099"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24873"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou235"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou004"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf065"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aeg3475"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01193-6"},{"key":"e_1_3_4_51_1","unstructured":"AZD2171 in treating patients with neurofibromatosis type 1 and plexiform neurofibroma and\/or neurofibroma near the spine. ClinicalTrials.Gov identifier: NCT00326872. Bethesda MD: National Library of Medicine; [cited 2026 Sep 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00326872"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70414-X"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25041"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now158"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-1053"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.168826"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63619-4"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdz045"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado6342"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02290-1"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0156"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.3791\/2558-v"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.3791\/68694"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110385"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-018-0163-y"},{"key":"e_1_3_4_66_1","unstructured":"Koselugo (selumetinib): summary of product characteristics. Amsterdam: European Medicines Agency; 2025 [cited 2026 Sep 26]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/koselugo"},{"key":"e_1_3_4_67_1","unstructured":"Koselugo (selumetinib): US prescribing information. Silver Spring MD: US Food and Drug Administration; 2025 [cited 2026 Sep 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219943s002lbl.pdf"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npae038"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac146"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000435744.57038.af"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdag180"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-51"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.01.028"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18152463"},{"key":"e_1_3_4_75_1","unstructured":"Intermittent dosing of selumetinib in childhood NF1-associated tumours (inspect). ClinicalTrials.Gov identifier: NCT03326388. Bethesda MD: National Library of Medicine; [cited 2026 Sep 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03326388"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2750237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2750237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2750237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:28:31Z","timestamp":1792117711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2750237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":73,"alternative-id":["10.1080\/14656566.2026.2750237"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2750237","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}